If you know the BIOSCURE ACT properly, you will know why it is certain to pass C

If you know the BIOSCURE ACT properly, you will know why it is certain to pass Congress. #Binex

1. Security issues - China's Wu Xu Bio took data.
The impetus to propose a legislation that prevents US companies from supporting foreign biotech companies originated from US intelligence that implicated WuXi AppTec, a leading Chinese CDMO, in the unauthorised sharing of sensitive US client data to Chinese entities. This was construed by the US intelligence as a “pattern of behaviour” aimed at furthering China’s technological and military capabilities. Accordingly, these companies are viewed as a threat to US national security by “engaging in joint research with, being supported by, or being affiliated with a foreign adversary’s military, internal security forces, or intelligence agencies.”

The trigger for the proposal of legislation to ban U.S. companies from supporting foreign biotech companies came from U.S. intelligence agencies, which implicated WuXi AppTec, China's leading CDMO, in sharing sensitive U.S. customer data with Chinese agencies without permission. U.S. intelligence agencies interpreted this as a "behavioral pattern" to bolster China's technological and military capabilities. Thus, such companies are seen as a threat to U.S. national security "by participating in, receiving support, or partnering with the military, internal security forces, or intelligence agencies of foreign adversaries."

2. The association has already approved the bill
Despite outcries on the challenges the Act would bring about, the Biotechnology Innovation Organisation (BIO), the world’s largest advocacy association representing biotechnology companies, assented to the act. Severance from WuXi AppTec will have financial ramifications as it is involved in a quarter of the drugs commercialised in the US.

Despite criticism of the challenges the bill will bring, the BIO, the world's largest advocacy organization that represents biotech companies, agreed to the bill. Its separation from WuXi AppTec would have financial repercussions because it would involve a quarter of drugs marketed in the United States.

If passed, the legislation would severely impact R&D, cause delays in clinical trials, and shortages in drug production. Although the legislation would not be fully operational by 2032, US companies have begun the search for alternatives to diversify supply chains.

Passing the bill would severely impact R&D, delay clinical trials and lead to drug production shortages. While the bill won't be fully implemented until 2032, U.S. companies have begun exploring alternatives to diversify their supply chains.